Starpharma’s stock price jumped 13.04% to $1.30 on 31 August 2018 after the AstraZeneca’s first patent application on Starpharma’s DEP dendrimer with AstraZeneca’s Bcl2/xL inhibitors got published by the World Intellectual Property organization.
The patent DEP Bcl2/xL conjugates can treat many cancers including leukemias. It is having the combination of Starpharma’s DEP delivery technology and AstraZeneca’s Bcl2/xL inhibitors, exhibiting compelling efficacy and synergy in combination. It is described as ‘best-in-class’ with a broad combination opportunity in both solid and hematological tumors.
Starpharma CEO, Dr Jackie Fairley commented: “AstraZeneca’s impressive data published today demonstrates that the DEP® Bcl2/xL conjugates are highly effective across a range of cancer types both alone and in combination with other anti-cancer agents.
Starpharma (ASX: SPL) can potentially achieve development, launch and sales milestones of US$124 million for the first DEP product, and US$93.3 million for each subsequent qualifying product under AstraZeneca multiproduct DEP license.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.